FDA Adverse Event Malfunction Summary report: N

BD MAX¿ VAGINAL PANEL

MDR report key: 15546921 · Received October 5, 2022

Report

Report Number
3007420875-2022-00060
Event Type
Malfunction
Date Received
October 5, 2022
Date of Event
September 28, 2022
Report Date
December 21, 2022
Manufacturer
GENEOHM SCIENCES CANADA, INC. (BD DIAGNOSTICS)
Product Code
PQA
UDI-DI
00382904437121
PMA / PMN Number
SEE H.10
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
LA, US
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

PMA/510(K)#: DEN160001. A DEVICE EVALUATION AND/OR DEVICE HISTORY REVIEW IS ANTICIPATED BUT IS NOT COMPLETE. UPON COMPLETION, A SUPPLEMENTAL REPORT WILL BE FILED.

Additional Manufacturer Narrative · 0

H.6 INVESTIGATION SUMMARY: THE COMPLAINT INVESTIGATION FOR HIGH POSITIVITY RATE FOR THE CANDIDA TARGET WITH THE BD MAX VAGINAL PANEL (REF. 443712) LOT 2110913 WAS PERFORMED BY THE REVIEW OF THE MANUFACTURING RECORDS, CUSTOMER¿S DATA ANALYSIS AND VERIFICATION OF COMPLAINTS HISTORY. REVIEW OF THE MANUFACTURING RECORDS OF BD MAX VAGINAL PANEL INDICATED THAT THE LOT 2110913 WAS MANUFACTURED ACCORDING TO SPECIFICATIONS AND MET PERFORMANCE REQUIREMENTS. MORE DETAILS ABOUT THE COMPLAINT WERE REQUESTED BUT NO MORE INFORMATION WAS PROVIDED THUS THE INVESTIGATION WAS LIMITED. MANUAL PCR CURVE ADJUDICATION WAS PERFORMED ACROSS SAMPLES INCLUDED IN BOTH RUNS. BOTH RUNS CONTAINING 20 SAMPLES TESTED WITH THE BD MAX VAGINAL PANEL ASSAY ON INSTRUMENT BD MAX CT2684. MULTIPLE SAMPLES GAVE A POSITIVE RESULT FOR THE CGROUP TARGET IN BOTH RUNS AND BASED ON THIS INFORMATION, IT WAS ASSUMED THAT THE COMPLAINT WAS RELATED TO THAT SPECIFIC TARGET. NO OTHER CANDIDA TARGET WAS POSITIVE. AMONG THE (B)(4) SAMPLES TESTED IN BOTH RUNS, 10 GAVE A POSITIVE CGROUP RESULT WITH AMPLIFICATION CURVES SUGGESTING TRUE POSITIVE RESULTS. NEVERTHELESS, MANUAL CURVE ADJUDICATION HAS LIMITATIONS; VISUAL EXAMINATION OF PCR CURVES FOR LOW SIGNAL IS A CONSERVATIVE ASSESSMENT OF THE DATA. THE DATABASE OF INSTRUMENT CT2684 INCLUDED 136 RUNS TESTED WITH VARIOUS ASSAYS OVER A PERIOD OF 3 MONTHS. (B)(4) SAMPLES WERE TESTED WITH THE BD MAX¿ VAGINAL PANEL ASSAY, ALL USING THE SAME KIT LOT 2110913. DATA ANALYSIS REVEALED THAT, WHEN EXCLUDING THE POSITIVE CONTROLS SAMPLES, THE POSITIVITY RATE FOR THE CGROUP TARGET VARIED IN TIME SUGGESTING THAT THE ISSUE IS NOT LINKED SPECIFICALLY TO THE KIT LOT. ON SEPTEMBER 27TH, CUSTOMER PERFORMED ENVIRONMENTAL MONITORING USING A SINGLE SAMPLE (SWAB OF MULTIPLE ZONES) AND IT GAVE A NEGATIVE RESULT SUGGESTING THAT THE ISSUE IS NOT LINKED TO HIGH LEVEL OF ENVIRONMENTAL CONTAMINATION. . OVERALL, NO REAGENTS ISSUE IS SUSPECTED. THERE IS NO INDICATION OF AN INCREASE IN COMPLAINTS FOR DISCREPANT RESULTS FOR THE BD MAX VAGINAL PANEL LOT 2110913. THE ROOT CAUSE WAS NOT IDENTIFIED. BD CANNOT CONFIRM THE COMPLAINT BASED ON THE INVESTIGATION THAT WAS PERFORMED. . BD APOLOGIZES FOR THE INCONVENIENCE THAT THIS MAY HAVE CAUSED. BD QUALITY WILL CONTINUE TO MONITOR FOR TRENDS. H3 OTHER TEXT : SEE H.10.

Description of Event or Problem · 0

IT WAS REPORTED THAT WHILE USING THE BD MAX¿ VAGINAL PANEL THERE WAS A HIGH POSITIVITY RATE FOR THE CANDIDA TARGET. NO PATIENT IMPACT WAS REPORTED. THE FOLLOWING INFORMATION WAS PROVIDED BY THE INITIAL REPORTER: CUSTOMER REPORTS MVP ASSAY "HIGH POSITIVITY RATE FOR CANDIDA TARGET", ACCORDING TO THEIR PROVIDERS.

Description of Event or Problem · 0

IT WAS REPORTED THAT WHILE USING THE BD MAX¿ VAGINAL PANEL THERE WAS A HIGH POSITIVITY RATE FOR THE CANDIDA TARGET. NO PATIENT IMPACT WAS REPORTED. THE FOLLOWING INFORMATION WAS PROVIDED BY THE INITIAL REPORTER: CUSTOMER REPORTS MVP ASSAY "HIGH POSITIVITY RATE FOR CANDIDA TARGET", ACCORDING TO THEIR PROVIDERS.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
2304368 BD MAX¿ VAGINAL PANEL VAGINITIS AND BACTERIAL VAGINOSIS NUCLEIC ACID DETECTION SYSTEM PQA GENEOHM SCIENCES CANADA, INC. (BD DIAGNOSTICS) 443712 UNKNOWN 00382904437121

Patients

Seq Age Sex Outcome Treatment
1 Unknown